<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515812</url>
  </required_header>
  <id_info>
    <org_study_id>10-075</org_study_id>
    <nct_id>NCT02515812</nct_id>
  </id_info>
  <brief_title>Comparative Study of Cardiac Adrenergic Function Explored by I-123-MIBG and CZT Camera (D-SPECT) Versus Anger Camera in Patients With Heart Failure</brief_title>
  <acronym>ADRECARD</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiological examination constitute one of the major directions in nuclear medicine for
      detection of myocardial ischemia in patients suspected of coronary disease. In Caen, they
      constitute 20% of the activity of nuclear medicine. Systolic heart failure (HF) ischemic or
      nonischemic origin represents a new area of activity of the nuclear cardiology. This is HF
      stratification study based on cardiac adrenergic function after injection of a tracer:
      I-123-MIBG. The team Caen nuclear cardiology is one of two teams recognized internationally
      in the field of evaluating the cardiac sympathetic innervation in cardiomyopathies. Numerous
      publications from 1992 to the present day have reported encouraging results for the daily use
      of this tracer in the evaluation of patients with LV dysfunction IC. Recently, interest in
      using the MIBG has been shown as a prognostic marker of HF in a prospective study of 961
      patients. Typically, the camera used was an Anger camera with collimating Nai standard called
      parallel holes.

      The main objective is to validate the measurements of cardiac adrenergic function evaluated
      by cardiopulmonary mediastinal reports and sympathetic innervation scores VG after injection
      of I-123-MIBG in 80 patients with heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SRSI (summed rest score innervation)</measure>
    <time_frame>4 hours after I-123-MIBG perfusion</time_frame>
    <description>with CZT camera and Anger camera</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SRS (summed rest score)</measure>
    <time_frame>4 hours after I-123-MIBG perfusion</time_frame>
    <description>with CZT camera and Anger camera</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Adrenergic Function Explorations with CZT camera</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>I-123-MIBG and CZT Camera (D-SPECT)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adrenergic Function Explorations with Anger camera</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>I-123-MIBG and Anger Camera</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>I-123-MIBG</intervention_name>
    <arm_group_label>Adrenergic Function Explorations with CZT camera</arm_group_label>
    <arm_group_label>Adrenergic Function Explorations with Anger camera</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CZT Camera (D-SPECT)</intervention_name>
    <arm_group_label>Adrenergic Function Explorations with CZT camera</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Anger Camera</intervention_name>
    <arm_group_label>Adrenergic Function Explorations with Anger camera</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above 18 years (except major patients under guardianship)

          -  patient who signed the consent form

          -  written and spoken French

          -  Beneficiaries of the social security system

          -  Stable heart failure with LV dysfunction (&lt;45%) of ischemic or nonischemic origin

        Exclusion Criteria:

          -  Patients with a recent history (&lt;21 days) acute coronary failure (myocardial
             infarction, unstable angina)

          -  Patients with severe extra-cardiac disease may interfere with treatment decisions
             (cancer, severe hepatic or renal impairment)

          -  Major patients under guardianship

          -  Pregnant or lactating women

          -  Women in age and condition of childbearing

          -  Patients unable to understand the purpose of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Médecine Nucléaire -CHU de Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <last_update_submitted>August 2, 2015</last_update_submitted>
  <last_update_submitted_qc>August 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenergic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

